DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 45.5 in the Healthcare sector.

What is the market capitalisation of Fredun Pharmaceuticals Ltd?

Fredun Pharmaceuticals Ltd has a market capitalisation of approximately ₹1,459 crore.

Fredun Pharmaceuticals Ltd

539730·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹1,459 Cr

P/E45.50

Vol—

Day—

52W300–999

Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

A steady, established business

O—H—L—PC—VWAP—VOL—

52W₹299.63

₹999.00

Snapshot

Key stats

Mkt Cap

₹1,459 Cr

P/E

45.50Expensive

P/B

5.51

ROE

15.80%Strong

ROCE

19.00%Efficient

52W High / Low

₹999 / ₹300

Div Yield

0.08%

EPS

₹14.65

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

45.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

15.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

19.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.80Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,459 Cr

P/B

5.51

EPS

₹14.65

Div Yield

0.08%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+32.5%

+36.7%

10Y

+31.3%

Profit

+43.6%

+74.8%

10Y

+41.7%

EPS

+67.0%

+85.6%

10Y

+37.7%

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 75.2% CAGR over last 5 years
Debtor days have improved from 87.9 to 53.2 days.
Company's median sales growth is 28.6% of last 10 years

Watch-outs

Cons

Promoter holding has decreased over last 3 years: -5.05%

More Healthcare stocks · Pharmaceuticals

Explore Fredun Pharmaceuticals Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.